EPISODE · Dec 11, 2019 · 34 MIN
When It Comes To Complex PTSD, Depression, Research Turns to Psychedelics For Treatment
from On Second Thought
People struggling with treatment-resistant PTSD may soon have a new course of care: MDMA. When used alongside psychotherapy, the synthetic substance in the drug more commonly known as ecstasy or molly is currently in phase three clinical trials. It’s even been given “breakthrough designation” by the FDA, a status reserved for treatments with significant potential to improve patient outcomes. But MDMA isn’t the only kind of party drug experiencing interest for therapeutic potential. Psilocybin, the active ingredient in "magic mushrooms", is being evaluated for its potential in alleviating depression. Guided ayahuasca trips are a growing trend, especially amongst Brooklyn and Silicon Valley elites.
Embed this episode
What this episode covers
People struggling with treatment-resistant PTSD may soon have a new course of care: MDMA. When used alongside psychotherapy, the synthetic substance in the drug more commonly known as ecstasy or molly is currently in phase three clinical trials. It’s even been given “breakthrough designation” by the FDA, a status reserved for treatments with significant potential to improve patient outcomes. But MDMA isn’t the only kind of party drug experiencing interest for therapeutic potential. Psilocybin,
NOW PLAYING
When It Comes To Complex PTSD, Depression, Research Turns to Psychedelics For Treatment
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.